Effects of Esomeprazole 40 mg Twice Daily on Asthma
Authors:
- Toni O. KiljanderTKToni O. Kiljander
- Susan M. HardingSHSusan M. Harding
- Stephen K. FieldSFStephen K. Field
- Mark R. SteinMSMark R. Stein
- Harold S. NelsonHNHarold S. Nelson
- Jan EkelundJEJan Ekelund
- Marta IlluecaMIMarta Illueca
- Ola BeckmanOBOla Beckman
- Mark B. SostekMSMark B. Sostek
- 15 May 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 173 (10) , 1091-1097
Abstract
Rationale: Gastroesophageal reflux disease (GERD) is common in patients with asthma, suggesting an interaction between the two conditions. Objectives: To assess the effect of gastric acid suppression with the proton pump inhibitor esomeprazole on asthma outcomes in subjects with persistent moderate to severe asthma treated with antiinflammatory asthma medication. Methods: In this double-blind study, subjects were randomized to receive esomeprazole 40 mg or placebo twice daily for 16 wk. According to nocturnal respiratory symptoms (NOC) and GERD, subjects were divided into three strata: GERD–/NOC+, GERD+/NOC–, and GERD+/NOC+. Measurements and Main Results: A total of 770 subjects were randomized. There was no statistically significant improvement in morning peak expiratory flow (PEF) over placebo in the overall study population: 6.3 L/min (p = 0.061). Over the whole treatment period, in GERD+/NOC+ subjects (n = 350), esomeprazole provided an 8.7-L/min improvement (p = 0.03) in morning PEF, and a 10.2-L/min improvement (p = 0.012) in evening PEF over placebo. Among 307 subjects taking long-acting β2-agonists, improvements over placebo were observed in morning PEF (12.2 L/min, p = 0.017) and in evening PEF (11.1 L/min, p = 0.024); these improvements were more pronounced in GERD+/NOC+ subjects. Esomeprazole 40 mg twice daily was well tolerated and no safety concerns were noted. Conclusions: Esomeprazole improved PEF in subjects with asthma who presented with both GERD and NOC. In subjects without both GERD and NOC, no improvement could be detected.Keywords
This publication has 27 references indexed in Scilit:
- NoticesGastroenterology, 2005
- Intragastric acid suppression and pharmacokinetics of twice‐daily esomeprazole: a randomized, three‐way crossover studyAlimentary Pharmacology & Therapeutics, 2004
- Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic reviewThorax, 2001
- EsomeprazoleDrugs, 2000
- Difficult asthmaEuropean Respiratory Journal, 1998
- Gastro-oesophageal reflux prevalence and relationship with bronchial reactivity in asthmaEuropean Respiratory Journal, 1997
- Adult asthma and gastro‐oesophageal reflux: the effects of omeprazole therapy on asthmaAustralian and New Zealand Journal of Medicine, 1996
- Asthma and gastroesophageal reflux: Acid suppressive therapy improves asthma outcomeThe American Journal of Medicine, 1996
- Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux?Digestive Diseases and Sciences, 1994
- Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-oesophageal reflux: a placebo-controlled cross-over studyPostgraduate Medical Journal, 1994